We are excited to announce that the Medical Affairs Summit Returns to Boston!

The Medical Affairs Summit is scheduled to take place on 12 – 13 October 2023 at the luxurious Encore Boston Harbor in Boston, MA, US. The event brings together key Clinical Trial Executives representing pharmaceutical industries in the Americas. The Summit offers a highly focused and interactive platform for attendees to address core concerns and find solutions tailored to their specific needs.

The Summit offers the opportunity for one-on-one business meetings, which allows sponsors to connect with key decision-makers in the industry. This can be instrumental in forging precious partnerships. This is an unparalleled opportunity for extensive networking among industry peers during one-on-one business meetings, event meals, cocktail receptions and leisure entertainment.

Previous attendees include:

  • Johnson & Johnson – Director, Global Program Leader – Oncology, Medical Affairs Operations
  • EMD Serono Inc.- Director, Strategic Planning and Performance Management
  • Janssen – Group Medical Director, Solid Tumors
  • Radius Health – Head: Medical Strategy & Integrated Evidence
  • Sobi Inc. – Director of Immunology, Medical Affairs
  • Vertex Pharmaceuticals – Medical Director

To enquire more information, please visit https://bit.ly/43CBrgl or directly contact Isidora Avraam at isidoraa@marcusevanscy.com.

#meMedAffairs

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”